OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Albitar on the Importance of Obtaining Genomic Testing in Oncology

November 3rd 2021

Maher Albitar, MD, discusses the importance of obtaining genomic testing in oncology.

Dr. Kremyanskaya on the Need for Disease-Modifying Approaches in MPNs

November 3rd 2021

Marina Kremyanskaya, MD, PhD, discusses the need for disease-modifying treatment approaches for patients with myeloproliferative neoplasms.

Dr. Kuykendall on the Potential for Momelotinib in Myelofibrosis

November 2nd 2021

Andrew T. Kuykendall, MD, discusses the potential for momelotinib in the treatment of patients with myelofibrosis.

Dr. Esteva on Therapeutic Developments in HER2+ Breast Cancer

November 2nd 2021

Francisco Javier Esteva, MD, PhD, discusses therapeutic developments for patients with HER2-positive breast cancer.

Dr. Baron on Contributing Factors for Developing Breast Cancer

November 2nd 2021

Paul Lawrence Baron, MD, discusses contributing factors for developing breast cancer.

Dr. Brown on the Promise of the ROCSAN Trial in Gynecologic Carcinosarcomas

November 2nd 2021

Jubilee Brown, MD, discusses the promise of the phase 2/3 ROCSAN trial in recurrent gynecologic carcinosarcomas.

Dr. Palmbos on Frontline Treatment Recommendations in Bladder Cancer

November 2nd 2021

Phillip Palmbos, MD, PhD, discusses updates and therapeutic recommendations for the frontline treatment of patients with bladder cancer.

Dr. Hubbard on MRD Assessment to Inform Treatment Decisions in Resected Metastatic CRC

November 2nd 2021

Joleen M. Hubbard, MD, discusses minimal residual disease assessment to inform treatment decisions in patients with resected metastatic colorectal cancer.

Dr. Danilov on the Rationale to Target MCL1 and BCLX in CLL

November 1st 2021

Alexey V. Danilov, MD, PhD, discusses the rationale to target MCL1 and BCLX in chronic lymphocytic leukemia.

Dr. Sabari on Selecting Between Available ALK inhibitors in ALK+ NSCLC

November 1st 2021

Joshua K. Sabari, MD, discusses selecting between available ALK inhibitors in ALK-positive non–small cell lung cancer.

Dr. Yentz on Navigating Frontline Treatment Selection in RCC

November 1st 2021

Sarah Elizabeth Yentz, MD, discusses navigating frontline treatment selection in renal cell carcinoma.

Dr. Salani on Future Research Opportunities in Recurrent Ovarian Cancer

October 29th 2021

Ritu Salani, MD, MBA, discusses future research opportunities for improving the treatment of patients with recurrent ovarian cancer.

Dr. Burns on Key Advances Made in RET+ NSCLC

October 29th 2021

Timothy F. Burns, MD, PhD, discusses key developments in the frontline treatment of patients with RET-positive non–small cell lung cancer.

Dr. Monk on Potential Shifts to Treatment Sequencing Strategies in Cervical Cancer

October 29th 2021

Bradley J. Monk, MD, FACS, FACOG, discusses potential shifts to treatment sequencing strategies in cervical cancer.

Dr. Girard on the Next Steps With Durvalumab in NSCLC

October 29th 2021

Nicolas Girard, MD, discusses the next steps with durvalumab in non–small cell lung cancer.

Dr. Johnson on the Potential of TROP2 as a Target for All-Comers With Solid Tumors

October 29th 2021

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

Dr. Dholaria on Patient Characteristics in the MagnetisMM-1 Trial in Multiple Myeloma

October 29th 2021

Bhagirathbhai Dholaria, MBBS, discusses patient characteristics in the phase 1 MagnetisMM-1 trial in relapsed/refractory multiple myeloma.

Dr. Subramanian on the Current Standard of Care in Stage III NSCLC

October 29th 2021

Janakiraman Subramanian, MD, discusses the standard of care in stage III non–small cell lung cancer.

Dr. Villaruz on Updates From the CheckMate-227 Trial With Nivolumab/Ipilimumab in NSCLC

October 28th 2021

Liza C. Villaruz, MD, discusses updated data from the phase 3 CheckMate-227 trial examining nivolumab with or without ipilimumab in patients with non–small cell lung cancer.

Dr. Venkat on Unmet Needs in Ovarian Cancer

October 28th 2021

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer.